Amyot S L, Leblanc M, Thibeault Y, Geadah D, Cardinal J
Departments of Intensive Care, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada.
Intensive Care Med. 1999 Oct;25(10):1169-72. doi: 10.1007/s001340051031.
Myoglobin has a relatively high molecular weight of 17,000 Da and is poorly cleared by dialysis (diffusion). However, elimination of myoglobin might be enhanced by an epuration modality based on convection for solute clearances. We present a single case of myoglobin-induced renal failure (peak creatine kinase level: 313,500 IU/l) treated by continuous venovenous hemofiltration (CVVH). Our purpose was to evaluate the efficiency of such a modality using an ultrafiltration rate of 2 to 3 l/h for myoglobin removal and clearance. The hemofilter was a 0.9 m(2) polyacrylonitrile (AN69) membrane Multiflow-100 (Hospal-Gambro, St-Leonard, Canada) and the blood flow rate was maintained at 150 ml/min by an AK-10 pump (Hospal-Gambro, St-Leonard, Canada). The ultrafiltration bag was placed 60 cm below the hemofilter and was free of pump control or suction device. Serum myoglobin concentration was 92,000 microg/l at CVVH initiation and dropped to 28,600 microg/l after 18 h of the continuous modality. The mean sieving coefficient for myoglobin was 0.6 during the first 9 h of therapy and this decreased to 0.4 during the following 7 h. Mean clearance of myoglobin was 22 ml/min, decreasing to 14 ml/min during corresponding periods, while the mean ultrafiltration rates were relatively stable at 2,153 +/- 148 ml/h and 2,074 +/- 85 ml/h, respectively. In contrast to myoglobin, the sieving coefficeint for urea, creatinine, and phosphorus remained stable at 1.0 during the first 16 h of CVVH. More than 700 mg of myoglobin were removed by CVVH during the entire treatment. In conclusion, considerable amounts of myoglobin can be removed by an extracorporeal modality allowing important convective fluxes and middle molecule clearances, such as CVVH at a rate of 2 to 3 l/h using an AN69 hemofilter. If myoglobin clearance had been maintained at 22 ml/min, 32 l of serum would have been cleared per day. However, the sieving coefficient of myoglobin decreased over time, probably as a consequence of protein coating and/or blood clotting of the hemofilter. Whereas myoglobin can be removed by CVVH, it remains unknown at this point if such a modality, applied early, can alter or shorten the course of myoglobinuric acute renal failure.
肌红蛋白分子量相对较高,为17,000道尔顿,通过透析(扩散)清除效果不佳。然而,基于对流的溶质清除净化方式可能会增强肌红蛋白的清除。我们报告一例经连续性静脉-静脉血液滤过(CVVH)治疗的肌红蛋白诱导的肾衰竭病例(肌酸激酶峰值水平:313,500 IU/l)。我们的目的是评估使用2至3 l/h的超滤率清除和净化肌红蛋白这种方式的效率。血液滤过器为0.9 m(2)的聚丙烯腈(AN69)膜Multiflow-100(加拿大圣莱昂纳德的Hospal-Gambro公司),通过AK-10泵(加拿大圣莱昂纳德的Hospal-Gambro公司)将血流速度维持在150 ml/min。超滤袋置于血液滤过器下方60 cm处,无泵控制或抽吸装置。CVVH开始时血清肌红蛋白浓度为92,000 μg/l,连续治疗18小时后降至28,600 μg/l。治疗的前9小时肌红蛋白的平均筛系数为0.6,随后7小时降至0.4。肌红蛋白的平均清除率为22 ml/min,相应时间段内降至14 ml/min,而平均超滤率相对稳定,分别为2,153±148 ml/h和2,074±85 ml/h。与肌红蛋白不同,CVVH治疗的前16小时尿素、肌酐和磷的筛系数保持在1.0稳定。整个治疗过程中CVVH清除了超过700 mg的肌红蛋白。总之,通过允许重要对流通量和中分子清除的体外方式,如使用AN69血液滤过器以2至3 l/h的速率进行CVVH,可以清除大量肌红蛋白。如果肌红蛋白清除率维持在22 ml/min,每天可清除32升血清。然而,肌红蛋白的筛系数随时间下降,可能是血液滤过器蛋白涂层和/或凝血的结果。虽然肌红蛋白可通过CVVH清除,但目前尚不清楚早期应用这种方式是否能改变或缩短肌红蛋白尿性急性肾衰竭的病程。